Allergan (NYSE:AGN) Given Daily Media Sentiment Rating of 0.20
Media headlines about Allergan (NYSE:AGN) have been trending somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Allergan earned a news impact score of 0.20 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.1481943639805 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- Allergan (AGN) Given a $265.00 Price Target by JPMorgan Chase & Co. Analysts (americanbankingnews.com)
- Allergan plc (AGN) : Investors may need a consensus Analysts Rating – Wall Street Morning (wallstreetmorning.com)
- Allergan CEO: We Are Looking at All Options to Create Shareholder Value – TheStreet.com (thestreet.com)
- Allergan (NYSE:AGN) Considering All Strategic Options ‘With A … – Benzinga (benzinga.com)
- Allergan’s (AGN) “Buy” Rating Reaffirmed at Royal Bank of Canada (americanbankingnews.com)
Several brokerages have commented on AGN. Vetr lowered Allergan from a “strong-buy” rating to a “buy” rating and set a $183.43 price objective on the stock. in a report on Thursday. JPMorgan Chase & Co. set a $265.00 target price on Allergan and gave the company a “buy” rating in a research report on Thursday. Leerink Swann raised their target price on Allergan from $237.00 to $242.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Argus downgraded Allergan from a “buy” rating to a “hold” rating and decreased their target price for the company from $256.80 to $160.07 in a research report on Thursday, December 7th. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $191.00 target price on shares of Allergan in a research report on Tuesday, February 6th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $224.02.
Allergan (NYSE:AGN) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, topping the Zacks’ consensus estimate of $4.74 by $0.12. Allergan had a positive return on equity of 8.43% and a negative net margin of 26.32%. The firm had revenue of $4.33 billion for the quarter, compared to the consensus estimate of $4.28 billion. During the same quarter last year, the business posted $3.90 earnings per share. The firm’s revenue was up 12.0% compared to the same quarter last year. analysts forecast that Allergan will post 15.58 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be given a $0.72 dividend. The ex-dividend date is Tuesday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.73%. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s payout ratio is currently -21.46%.
In other Allergan news, Director Joseph H. Boccuzi bought 900 shares of Allergan stock in a transaction on Monday, March 5th. The shares were bought at an average price of $143.42 per share, for a total transaction of $129,078.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Matthew M. Walsh bought 2,000 shares of Allergan stock in a transaction on Wednesday, February 21st. The stock was acquired at an average price of $160.94 per share, for a total transaction of $321,880.00. The disclosure for this purchase can be found here. Insiders acquired 7,200 shares of company stock worth $1,108,267 in the last 90 days. Company insiders own 0.36% of the company’s stock.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.